Antoni Bayes-Genis
Autonomous University of Barcelona
821 Papers
2.6K Citations
Antoni Bayes-Genis is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Medicine & Heart failure. The author has an hindex of 60, co-authored 639 publications. Previous affiliations of Antoni Bayes-Genis include University of Alberta & Hospital de Sant Pau.
Chat about Author
Papers
Ratio between left and right ventricular end-diastolic volumes and outcomes in patients with heart failure and preserved ejection fraction
Alberto Aimo,Albert Teis,G. Kasa,Gladys Juncà,Josep Lupón,Mar Domingo,Elena Ferrer,Nuria Vallejo,Germán Cediel,Pau Codina,Jorge López-Ayerbe,N Martini,Michele Emdin,Antoni Bayes-Genis,Victoria Delgado +14 more
TL;DR: The relative dilation of the LV compared to the RV among patients with HF and preserved LV ejection fraction (HFpEF) was investigated and the association between LV/RV ratio (defined as the ratio between LV end-diastolic volume index [LVEDVi] and RV end- diastolicVolume index [RVEDVi]) and outcomes and outcomes was explored.
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions
TL;DR: A very recent review by Prof. Braunwald told the amazing story of sodium–glucose cotransporter 2 inhibitors (SGLT2i), from the discovery of their glycosuric properties in the late 19th century to the unexpected finding of their great efficacy in patients with heart failure.
1
Acute Heart Failure: The Unrecognized Epidemic
TL;DR: Esta «Puesta al dia» presta especial atencion al valor de los biomarcadores y fundamentalmente del NTproBNP (fragmento aminoterminal del propeptido natriuretico cerebral) en the ICA, no solo como complemento diagnostico sino tambien por su alto valor pronostico.
1
ST2-Based Precision Medicine in Device Management: the Next Frontier Beyond MADIT-CRT?
TL;DR: The cancer-focused component of this initiative will be designed to address some of the obstacles that have already been encountered in precision oncology: unexplained drug resistance, genomic heterogeneity of tumors, insufficient means for monitoring responses and tumor recurrence, and limited knowledge about the use of drug combinations.
No urgent need for revisiting kalaemia guidelines: rebuttal.
TL;DR: The rebuttal letter to the counterpoint on kalaemia levels in guidelines read with interest, and counter-arguments to the already discussed items are provided, stressing a couple of issues that may have gone unnoticed or that may not have emphasized enough.
1